NCT06128863View on ClinicalTrials.gov

Pembrolizumab in Combination with Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients with Soft Tissue Sarcoma - EFTISARC-NEO Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2027

Conditions
NeoadjuvantImmunotherapySarcoma,Soft TissueRadiation Therapy
Interventions
DRUG

Pembrolizumab, Eftilagimod alpha

Eftilagimod alpha 20 mg s.c. every 2 weeks (5 doses), Pembrolizumab 200 mg i.v. every 3 weeks (3 cycles), Radiotherapy 50 Gy (25 x 2 Gy)

Trial Locations (1)

00-738

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw

All Listed Sponsors
collaborator

Immutep S.A.S.

INDUSTRY

lead

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER